In the 90 days prior to the date of this filing, there has been one additional insider transaction which has resulted in the acquisition of 667,292 of company shares. This compares with the preceding 90-day window of time where there were 10 transactions from 9 insiders which resulted in the net acquisition of 43,331 shares.
This is lower than the average level of insider transactions in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Within the peer group activity averaged 51.5 transactions per company, with company insiders acquiring on average 22,487 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1479290/000162828020014083/xslF345X03/wf-form4_160151529655460.xml
|Midday Report: Wall Street Battered on Tech Stocks, ...|
|First Oil: Baker Hughes Rig Count:|
|--GATX Maintains Quarterly Dividend At $0.48 a Share...|
|US TREASURIES: Bond Prices Give Up Early Gains, Flip...|
|Research Alert: CFRA Maintains Strong Buy Opinion On...|